Cenexi turnaround execution risk
Cenexi's performance has been below expectations, with losses persisting due to remediation activities and equipment breakdowns. Achieving positive EBITDA by Q3 FY26 is uncertain.
GLAND / Q4-FY25 / risks
Keep the risk register visible.
Gland Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
U.S. tariff impact on generics
The U.S. administration's reciprocal tariffs create uncertainty for Indian pharma companies. While management expects minimal impact on generics, the situation remains fluid.
ROW market tender losses
The ROW segment saw a 14% revenue decline in Q4 due to tender misses and softer offtake. Recovery depends on re-engaging local partners and executing a non-Enoxa strategy.
Cenexi capital allocation concerns
Analysts questioned the return on invested capital for Cenexi, given the high acquisition cost and additional capex. Management's target of 18% EBITDA on $300M revenue may still yield suboptimal ROCE.